Between September 2025 and March 2026, the FDA sent warning letters to more than 85 telehealth companies marketing compounded GLP-1 products. If that number doesn't register as alarming, consider the context: the agency issued more enforcement actions against GLP-1 telehealth platforms in nine months than it had against the entire telehealth industry in the previous five years.

This wasn't compliance theater. The Department of Health and Human Services referred several major players to the Department of Justice for criminal investigation in February 2026. The FDA has signaled that product seizures are on the table. And the agency's March 2026 batch of 30 warning letters came with language that reads less like regulatory guidance and more like a countdown.

85+
FDA warning letters to GLP-1 telehealth companies since September 2025

What the FDA Actually Found

The warning letters cite a consistent pattern of violations across the platforms targeted. Understanding these patterns is the fastest way to evaluate whether your own telehealth provider might be operating outside the lines.

False equivalence claims

The most common violation: marketing language that implies compounded GLP-1 products are the same as, equivalent to, or interchangeable with FDA-approved medications. Phrases the FDA specifically flagged include "same active ingredient as Ozempic," "generic Zepbound," "from the same family as Mounjaro," and similar constructions that blur the line between a regulated pharmaceutical product and a compounded alternative.

Obscured pharmacy sourcing

Multiple platforms were cited for failing to clearly identify which compounding pharmacy was producing the medication. Some used branding and packaging that gave the impression of a single integrated company, when in reality the telehealth platform, clinical entity, and pharmacy were three separate organizations with different ownership and regulatory oversight.

Misleading efficacy claims

Citing clinical trial data from Wegovy or Zepbound studies and applying those results to compounded products — which have not undergone the same testing — is a direct violation. The FDA makes clear that compounded medications are not FDA-approved and cannot borrow the safety and efficacy profiles of branded products.

Inadequate prescriber oversight

Some warning letters addressed platforms where the clinical evaluation was so minimal that it didn't meet the standard of a legitimate provider-patient relationship. In these cases, the platform was essentially functioning as a medication vending machine with a prescriber rubber-stamp.

Featured Provider
Embody
Injectable semaglutide programs with clinical oversight
Embody provides physician-supervised injectable semaglutide programs. Independently verify any provider's compliance status before enrolling.
Learn More About Embody →
Paid link · Advertising disclosure

The Timeline That Matters

Understanding the escalation pattern shows where this is heading:

Each action is more aggressive than the last. The pattern isn't ambiguous: the FDA is moving toward a world where mass-marketed compounded GLP-1s are no longer tolerated.

How to Audit Your Own Provider in 60 Seconds

You don't need a law degree to evaluate whether your telehealth platform is operating responsibly. Run through these checks:

  1. Check their website language: Do they use phrases like "same as Wegovy" or "generic semaglutide"? Those are the exact claims the FDA flagged. Legitimate providers are explicit that compounded medications are not FDA-approved.
  2. Identify the prescriber: Can you find the name and credentials of the clinician who reviewed your case? Is it a physician, NP, or PA? In which state are they licensed?
  3. Identify the pharmacy: Do they tell you which compounding pharmacy fills your prescription? Can you verify that pharmacy's license and LegitScript certification?
  4. Check for informed consent: Were you told — in writing — that your medication is compounded and not FDA-approved? Did you sign an informed consent document?
  5. Look for follow-up protocols: Does the platform require follow-up visits? At what intervals? Or did you get a prescription and never hear from anyone again?
Key Takeaway: If your telehealth provider's marketing looks like it could have been written by the FDA's warning letter examples, that's not a coincidence — it's a red flag. The platforms that will survive the current regulatory environment are the ones that are transparent about what compounded medications are and aren't.
Care Bare Rx
Streamlined GLP-1 intake and prescription process
Verify any provider's regulatory standing before enrolling. Look for clear labeling, pharmacy identification, and informed consent processes.
Visit Care Bare Rx → Paid link

What This Means for Patients Currently on Compounded GLP-1s

If you're currently receiving compounded semaglutide or tirzepatide from a telehealth platform, don't panic — but do pay attention. Warning letters are not product recalls. Your medication isn't being seized (yet). But the trajectory of enforcement is clear, and the platforms that received warning letters have limited time to come into compliance.

Practical steps: ask your provider directly whether they received an FDA warning letter and what changes they've made in response. If they won't answer or claim they don't know, that tells you something. Start researching alternative providers now — including platforms that offer branded FDA-approved medications — so you're not scrambling if your current provider shuts down or changes its offerings.

Sesame Care
Brand-name FDA-approved GLP-1 prescriptions
Sesame Care provides access to brand-name, FDA-approved GLP-1 medications only.
Sesame Care provides access to brand-name, FDA-approved GLP-1 medications through licensed prescribers.
Visit Sesame Care → Paid link
FDA Compounding Disclaimer: Compounded medications are not FDA-approved. They are prepared by compounding pharmacies based on individual prescriptions. The FDA does not verify the safety, efficacy, or quality of compounded drugs. Patients should discuss the risks and benefits with their prescriber.
Related Articles
Is GLP-1 Telehealth Safe? What the Research Shows →How to Verify if a GLP-1 Telehealth Provider Is Legitimate →Best GLP-1 Telehealth Platforms in 2026 →
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. GLP-1 receptor agonists carry risks including but not limited to gastrointestinal side effects, pancreatitis, gallbladder disease, and thyroid concerns. Individual results vary. This site contains affiliate links — see our advertising disclosure for details.